Kranus Health

Urology covers some of the most prevalent chronic conditions in adult medicine. Erectile dysfunction affects 80 million men in the US and EU. Prostate enlargement affects 130 million more. Urinary incontinence affects 200 million people across both sexes. Together, these conditions touch a larger share of the adult population than almost any other disease category. Nearly all of them go undertreated.

The gap is not clinical. Effective treatments exist for most of these conditions. The gap is structural. Urology has been one of the slowest medical specialties to digitize. Most patients reach care only once symptoms become severe enough to justify a specialist referral, often months or years after onset. Primary care handles the first presentation without the tools to manage it well, and the distance between first symptoms and effective treatment extends both the condition and its cost.

Digital therapeutics close that gap at a fraction of in-person care costs. When clinically validated and reimbursed through statutory health systems, they turn a broken access pathway into a scalable one. That transition is already underway in Germany and France. The addressable market is a 27 billion dollar global urology sector that remains almost entirely without digital infrastructure.

By the time we met Kranus, we had built conviction across digital health in under-served patient populations: Clue in reproductive health, Ouihelp in elderly care, Conceivable in fertility. The pattern was the same each time: a large patient group, a condition treated with inadequate tools, and a regulatory pathway that creates a durable position once cleared.

Urology fit that pattern precisely. Jens Nortershäuser, Nikolay Dimolarov and Kurt Miller had navigated both the clinical validation and the regulatory approval that keeps most digital health companies permanently in pilots. More than 10,000 patients treated, a satisfaction score of 9.5 out of 10, and live reimbursement in Germany are the milestones that separate a digital health company that works from one that pitches. The expansion into France and forthcoming product lines for uro-oncology extend the platform across a 27 billion dollar global urology market. We backed the team, the model and the gap.